Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases

Journal of Controlled Release

Volumn 183, Issue 1, 2014, Pages 167-177

  Ali, H ^a   Weigmann, B ^b   Neurath, M F ^b   Collnot, E M ^a,c   Windbergs, M ^a   Lehr, C M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c URSAPHARM Arzneimittel GmbH   (Germany)

Author keywords

Colitis; Cytokines; DSS; Mini endoscopy; Oxazolone; TNBS

Indexed keywords

ALKALINITY; COATINGS; COPOLYMERS; DRUG DELIVERY; DRUG DOSAGE; DRUG PRODUCTS; EMULSIFICATION; MAMMALS; NANOPARTICLES;

COLITIS; CYTOKINES; DSS; MINI-ENDOSCOPY; OXAZOLONE; TNBS;

DISEASES;

BUDESONIDE; COPOLYMER; CYTOKINE; GLUCOSE; METHACRYLIC ACID METHYL ESTER; MYELOPEROXIDASE; NANOCARRIER; NANOCOATING; POLYGLACTIN; ANTIINFLAMMATORY AGENT; DRUG CARRIER; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ACIDITY; ACUTE DISEASE; ALKALINITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; ENDOSCOPE; ENZYME ACTIVITY; EXPERIMENTAL COLITIS; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE ENDOSCOPY; INTESTINE MUCOSA; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; TARGET ORGAN; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PH; SURFACE PROPERTY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; HYDROGEN-ION CONCENTRATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LACTIC ACID; METHYLMETHACRYLATE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SURFACE PROPERTIES;

EID: 84898804695     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.03.039     Document Type: Article

References (44)

1. R. Odze Diagnostic problems and advances in inflammatory bowel disease Mod. Pathol. 16 4 2003 347 358 (Pubitemid 36443984)
2. M.T. Abreu The pathogenesis of inflammatory bowel disease: translational implications for clinicians Curr. Gastroenterol. Rep. 4 6 2002 481 489
3. S.B. Hanauer Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities Inflamm. Bowel Dis. 12 Suppl. 1 2006 S3 S9
4. G.P. de Chambrun, L. Peyrin-Biroulet, M. Lemann, and J.F. Colombel Clinical implications of mucosal healing for the management of IBD Nat. Rev. Gastroenterol. Hepatol. 7 1 2010 15 29
5. G.R. Lichtenstein, M.T. Sbreu, R. Cohen, and W. Tremaine American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease] Rev. Gastroenterol. Mex. 71 3 2006 351 401
6. A. Lamprecht Multiparticulate systems in the treatment of inflammatory bowel disease Curr. Drug Targets Inflamm. Allergy 2 2 2003 137 144
7. A. Lamprecht, N. Ubrich, H. Yamamoto, P. Maincent, Y. Kawashima, and C.M. Lehr Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease J. Pharmacol. Exp. Ther. 299 2 2001 775 781
8. Y. Meissner, Y. Pellequer, and A. Lamprecht Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery Int. J. Pharm. 316 1-2 2006 138 143 (Pubitemid 43765696)
9. M.P. Desai, V. Labhasetwar, G.L. Amidon, and R.J. Levy Gastrointestinal uptake of biodegradable microparticles: effect of particle size Pharm. Res. 13 12 1996 1838 1845 (Pubitemid 27034116)
10. J. Chen, C. Wu, and D. Oupicky Bioreducible hyperbranched poly(amido amine)s for gene delivery Biomacromolecules 10 10 2009 2921 2927
11. C. Lin, Z.Y. Zhong, M.C. Lok, X.L. Jiang, W.E. Hennink, J. Feijen, and J.F.J. Engbersen Novel bioreducible poly(amido amine)s for highly efficient gene delivery Bioconjug. Chem. 18 1 2007 138 145 (Pubitemid 46146003)
12. R.G. Parmar, M. Busuek, E.S. Walsh, K.R. Leander, B.J. Howell, L. Sepp-Lorenzino, and E. Kemp et al. Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics Bioconjug. Chem. 24 4 2013 640 647
13. B. Xiao, H. Laroui, S. Ayyadurai, E. Viennois, M.A. Charania, Y. Zhang, and D. Merlin Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy Biomaterials 34 30 2013 7471 7482
14. A. Lamprecht, H. Yamamoto, H. Takeuhi, and Y. Kawashima A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles J. Control. Release 104 2 2005 337 346 (Pubitemid 40724934)
15. M. Rodriguez, J.L. Vila-Jato, and D. Torres Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region J. Control. Release 55 1 1998 67 77 (Pubitemid 28477565)
16. M. Rodriguez, J.A. Antunez, C. Taboada, B. Seijo, and D. Torres Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats J. Pharm. Pharmacol. 53 9 2001 1207 1215 (Pubitemid 32904015)
17. N. Esmailpour, P. Hogger, and P. Rohdewald Binding kinetics of budesonide to the human glucocorticoid receptor Eur. J. Pharm. Sci. 6 3 1998 219 223 (Pubitemid 28473222)
18. R. Lofberg, P. Rutgeerts, H. Malchow, C. Lamers, A. Danielsson, G. Olaison, D. Jewell, and O. Ostergaard Thomsen et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study Gut 39 1 1996 82 86 (Pubitemid 26239111)
19. J.C. Leroux, E. Allemann, E. Doelker, and R. Gurny New approach for the preparation of nanoparticles by an emulsification-diffusion method Eur. J. Pharm. Biopharm. 41 1 1995 14 18
20. D.F. Evans, G. Pye, R. Bramley, A.G. Clark, T.J. Dyson, and J.D. Hardcastle Measurement of gastrointestinal pH profiles in normal ambulant human-subjects Gut 29 8 1988 1035 1041
21. S. Wirtz, C. Neufert, B. Weigmann, and M. Fe Neurath Chemically induced mouse models of intestinal inflammation Nat. Protoc. 2 3 2007 541 546 (Pubitemid 47040018)
22. C. Becker, M.C. Fantini, S. Wirtz, A. Nikolaev, R. Kiesslich, H.A. Lehr, P.R. Galle, and M.F. Neurath In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy Gut 54 7 2005 950 954 (Pubitemid 40873907)
23. S. Wirtz, C. Becker, R. Blumberg, P.R. Galle, and M.F. Neurath Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA J. Immunol. 168 7 2002 411 420 (Pubitemid 34014143)
24. B. Weigmann, H.A. Lehr, G. Yancopoulos, D. Valenzuela, A. Murphy, S. Stevens, J. Schmidt, P.R. Galle, S. Rose-John, and M.F. Neurath The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis J. Exp. Med. 205 9 2008 2099 2110
25. F. Heller, I.J. Fuss, E.E. Nieuwenhuis, R.S. Blumberg, and W. Strober Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells Immunity 17 5 2002 629 638 (Pubitemid 35351508)
26. G.P. Morris, P.L. Beck, W.T. Herridge, M.R. Szewczuk, and J.L. Wallace Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology 96 3 1989 795 803 (Pubitemid 19057602)
27. M.F. Neurath, I. Fuss, B.L. Kelsall, E. Stuber, and W. Strober Antibodies to interleukin 12 abrogate established experimental colitis in mice J. Exp. Med. 182 5 1995 1281 1290
28. J.E. Krawisz, P. Sharon, and W.F. Stenson Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity - assessment of inflammation in rat and hamster models Gastroenterology 87 6 1984 1344 1350 (Pubitemid 15201434)
29. Y. Xia, and J.L. Zweier Measurement of myeloperoxidase in leukocyte-containing tissues Anal. Biochem. 245 1 1997 93 96 (Pubitemid 27053423)
30. Y. Ruckert, U. Schindler, T. Heinig, S. Nikolaus, A. Raedler, and S. Schreiber IL-4 signaling mechanisms in inflammatory bowel disease mononuclear phagocytes Inflamm. Bowel Dis. 2 4 1996 244 252 (Pubitemid 126727735)
31. A. Thiesen, G.E. Wild, K.A. Tappenden, L. Drozdowski, M. Keelan, B.K.A. Thomoson, M.I. McBurney, M.T. Clandinin, and A.B.R. Thomson The locally acting glucocorticosteroid budesonide enhances intestinal sugar uptake following intestinal resection in rats Gut 52 2 2003 252 259 (Pubitemid 36115068)
32. F. Leonard, H. Ali, E. m Collonot, B.J. Crielaard, T. Lammers, G. Storm, and C.M. Lehr Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model ALTEX 29 3 2012 275 285
33. G.R. Greenberg, B.G. Feagan, F. Martin, L.R. Sutherland, A.B.R. Thomson, C.R. Williams, L.G. Nilsson, and T. Persson et al. Oral budesonide for active Crohn's disease N. Engl. J. Med. 331 13 1994 836 841 (Pubitemid 24289710)
34. G. Jonsson, A. Astrom, and P. Andersson Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver Drug Metab. Dispos. 23 1 1995 137 142
35. M. Leuschner, K.P. Maier, J. Schlichting, S. Strahl, G. Herrmann, H.H. Dahm, H. Ackermann, J. Happ, and U. Leuschner et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial Gastroenterology 117 4 1999 918 925 (Pubitemid 29468235)
36. S. Edsbacker, P. Andersson, C. Lindberg, J. Paulson, A. Ryrfeldt, and A. Thalen Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects Drug Metab. Dispos. 15 3 1987 403 411 (Pubitemid 17096525)
37. J. Gottfries, S. Melgar, and E. Michaelsson Modelling of mouse experimental colitis by global property screens: a holistic approach to assess drug effects in inflammatory bowel disease PLoS One 7 1 2012
38. P. Alex, N.C. Zachos, T. Nguyen, L. Gonzales, T.E. Chen, L.S. Conklin, M. Centola, and X.H. Li Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis Inflamm. Bowel Dis. 15 3 2009 341 352
39. B. Begue, H. Wajant, J.C. Bambou, L. Dubuquoy, D. Siegmund, J.F. Baeulieu, D. Canioni, and D. Berrebi et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions Gastroenterology 130 7 2006 1962 1974 (Pubitemid 43816954)
40. Y. Elitsur, Y. Elitsur, S.N. Lichtman, C. Neace, J. Dosescu, and J.A. Moshier Immunosuppressive effect of budesonide on human lamina propria lymphocytes Immunopharmacology 38 3 1998 279 285 (Pubitemid 28064598)
41. M. Niessner, and B.A. Volk Phenotypic and immunoregulatory analysis of intestinal T-cells in patients with inflammatory bowel-disease - evaluation of an in-vitro model Eur. J. Clin. Invest. 25 3 1995 155 164
42. R. Karttunnen, E.J. Breese, J.A. Walker-Smith, and T.T. MacDonald Decreased mucosal interleukin-4 (IL-4) production in gut inflammation J. Clin. Pathol. 47 11 1994 1015 1018
43. A. Lamprecht, U. Schafer, and C.M. Lehr Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa Pharm. Res. 18 6 2001 788 793 (Pubitemid 32783514)
44. C. Schmidt, C. Lautenschlaeger, E.M. Collnot, M. Schumann, C. Bojarski, J.D. Schulzke, C.M. Lehr, and A. Stallamch Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients J. Control. Release 165 2 2013 139 145